In ovarian cancer, SPP1+ tumor-associated macrophages (TAMs) promote immune suppression and T cell exhaustion (TEX) through the SPP1–CD44 axis, highlighting this pathway as a promising therapeutic target for reprogramming the immunosuppressive tumor microenvironment and improving patient outcomes (125). This evidence concerns the gene SPP1 and ovarian carcinoma.